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Abstract
Background: Infections may increase the risk for venous thromboembolism (VTE), but little is known about VTE risk
associated with community-acquired bacteraemia (CAB). We examined the risk for VTE within one year of CAB in
comparison to that in matched controls.
Methods: We conducted a population-based cohort study in North Denmark 1992–2011, using data from high-quality
health-care databases. We included 4,213 adult CAB patients who had positive blood cultures drawn on the day of hospital
admission, 20,084 matched hospitalised controls admitted for other acute medical illness, and 41,121 matched controls
from the general population. We computed 0–90 and 91–365 day absolute risks for hospital-diagnosed VTE and used
regression analyses with adjustment for confounding factors to compare the risk for VTE in bacteraemia patients and
controls.
Results: Among CAB patients, 1.1% experienced VTE within 90 days of admission and 0.5% during 91–365 days after
admission. The adjusted 90-day odds ratio (OR) for VTE was 1.9 (95% CI 1.4–2.7) compared with hospitalised controls, and
23.4 (95% CI 12.9–42.6) compared with population controls. During 91–365 days after CAB admission, the VTE risk remained
moderately increased (adjusted hazard ratio vs. hospitalised controls, 1.4; 95% CI 0.8–2.5, and vs. population controls, 1.9;
95% CI 1.0–3.3). Compared to hospitalised controls, the 90-day VTE risk increase was greater for Gram-positive infection
(adjusted OR 2.5; 95% CI 1.6–4.1) than for Gram-negative infection (adjusted OR, 1.2; 95% CI 0.7–2.1), partly due to a high
risk after Staphylococcus aureus infection (3.6%).
Conclusion: The risk for VTE is substantially increased within 90 days after community-acquired bacteraemia when
compared to hospitalised controls and population controls. However, the absolute risk of VTE following CAB is low.
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Introduction
Hospitalisations for community-acquired bacteraemia (CAB)
have increased by 50% in recent years [1]. Venous thromboem-
bolism (VTE) is a potentially life-threatening complication in
hospitalised medical patients, and any association between CAB
and VTE is therefore clinically important. The extent to which
infections may cause VTE is debated. Previous observational
studies have found 28-day or in-hospital risks of 0.5–1.5% for
symptomatic VTE in patients hospitalised for sepsis or severe
sepsis [2,3] and a 1-year risk of 1.9% after hospitalisation for sepsis
[2]. In acutely hospitalised medical patients, two studies have
identified infection as an independent risk factor for VTE (odds
ratio 1.27 and 1.74, vs. patients hospitalised for other disease)
[4,5]. Also, a recent case-control study found that patients
hospitalised with infection had a 5- to 12-fold increased risk for
VTE within 2 weeks after infection compared to population
controls, and that this risk increase waned over time but remained
significantly elevated for up to 1 year [6]. Cohort studies with long-
term follow-up of VTE-risk after infection are sparse [2,7], and
none has included a comparison group. Previous studies have also
lacked microbiological confirmation of infection, which may lead
to a falsely inflated association due to possible misdiagnosis of
VTE as skin infection or pneumonia.
We aimed to assess the short- and longer-term risks of
symptomatic VTE in a cohort of hospitalised medical patients
with microbiologically confirmed CAB compared with acutely
hospitalised controls and with the background population.
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Materials and Methods
Ethics Statement
This study was approved by the Danish Data Protection Agency
(2011-41-5864). In accordance with Danish law, informed consent
was not required for this study because it was entirely register-
based.
Design
We conducted this population-based cohort study in the North
Denmark Healthcare Region, where all ,500,000 inhabitants are
provided with free tax-supported health care. All blood culture
analyses in the Region are performed at the region’s referral
hospital, Aalborg University Hospital, which provides inpatient
care along with a dwindling number of district hospitals (from nine
to five).
In Denmark, all residents are assigned a unique Civil
Registration System (CRS) number which is registered in the
CRS and in all medical registries. The CRS also stores
information on date of birth, residency status, dates of immigra-
tion/emigration and death, updated daily. We used concatenated
data from the CRS, the North Denmark Bacteraemia Database
[8], the regional Hospital Discharge Registry (HDR) [9], and the
Aarhus University Prescription Database [10].
For this study, we defined CAB as the presence of viable
bacteria or fungi in the bloodstream isolated from blood cultures
taken on the day of hospital admission, among patients who had
not been admitted to hospital within the previous 30 days. The
North Denmark Bacteraemia Database, which is described in
detail elsewhere [8], was used for information on clinically relevant
bacteraemia episodes, including date of blood culture draw,
infectious agent, and focus of infection.
The HDR contains International Classification of Disease
diagnosis code data (ICD, versions 8 and 10) on hospital
discharges since 1977 and outpatient contacts since 1995 [9]. It
allows for one primary diagnosis code (condition that prompted
patient admission and the main condition responsible for the
completed diagnosis and treatment course) and up to twenty
secondary codes with no information as to which disease occurred
first. We considered primary and secondary VTE codes from
inpatient stays and hospital outpatient clinic visits as outcome
events during 1992–2011. We specifically did not include VTE-
diagnoses from emergency room visits because these codes may
have a positive predictive value of only 31% [11]. The prescription
registry details Anatomical Therapeutic Chemical Classification
(ATC) codes on reimbursed prescriptions in the North Denmark
region since 1989. We used the HDR and the prescription
database for information on risk factors for VTE: cancer,
cardiovascular disease, diabetes, obesity, chronic obstructive
pulmonary disease, renal disease, recent hospital admission, recent
surgery or trauma, and pregnancy [12]. The corresponding ICD
and ATC codes can be found in Supplementary Table S1.
Study Subjects
Eligibility criteria for all CAB patients and controls were age
$15 years, residence in the study area for $1 year, no hospital
stay in the previous 30 days, no history of bacteraemia, and no
previous hospital contact with a VTE diagnosis.
We identified all eligible acutely ill medical (non-surgical)
patients who had positive blood cultures taken on the day of
admission during 1992–2010. To be confident that CAB preceded
VTE in these cases, we first identified the patients (n = 26) who
had been given a VTE code at discharge from a CAB
hospitalisation since 1992. We then examined a convenience
sample of cases with available medical files and discharge files, i.e.
all cases since 1994 (n= 22, 85%). We found no indication of
reverse causation in any patient. Seventeen patients developed
VTE during their hospitalisation with CAB, and another five
patients had had symptoms of infection for two to seven days
before being diagnosed with both CAB and VTE on the day of
admission.
Next, we identified two separate comparison cohorts. Because
subsequent VTE risk may be related to acute medical hospital stay
rather than to infection per se, we assembled a matched hospitalised
comparison cohort of up to five acutely hospitalised patients for
each CAB patient. As the CAB patients, hospitalised controls were
admitted to medical departments, i.e. non-surgical and non-
psychiatric departments. We excluded controls who were hospi-
talised because of VTE, i.e., who had a primary diagnosis of VTE
from their index admission. The matching factors were sex, exact
year of birth, and exact calendar year of hospital admission.
Furthermore, for each CAB patient, we chose up to 10 eligible
population controls, who were alive on the index date ( = date of
hospital admission of the CAB patient), matched on sex and exact
year of birth.
Statistics
We followed all study subjects from the index date until first
hospital encounter for VTE, death, emigration out of Denmark, or
January 1st 2012, whichever came first. We first computed
absolute risks for VTE within 0–90 days and 91–365 days after
the index date. Next, we used conditional logistic regression to
compute odds ratios (ORs) with 95% confidence intervals (CIs) of
VTE within 0–90 days and Cox proportional hazards models
(stratified on matched groups) to compute hazard ratios (HRs) with
95% CIs of VTE during 91–365 days after the index date. Because
VTE events were uncommon in CAB patients and controls during
0–90 days, odds ratios approximate relative risks and may be
interpreted as such [13]. ORs and HRs for all CAB patients vs.
matched controls were controlled for matching factors (age,
gender, calendar-time) and further adjusted for cancer (yes/no),
cardiovascular disease (yes/no), other comorbidity (diabetes,
obesity, COPD, or renal disease - yes/no), and recent hospital
contact (yes/no). Subgroup analyses were performed according to
age group, gender, time period, causative pathogen(s), and focus of
infection. These were controlled for matching factors and further
adjusted for any comorbidity (cancer, cardiovascular disease,
diabetes, obesity, COPD, or renal disease - yes/no).
Because the risk of VTE in the 90 days after CAB may be
influenced more by the hospitalisation itself than by the CAB, in
comparisons with the general population we also computed
adjusted ORs of VTE during the CAB index admission vs.
matched population controls experiencing VTE during 0–90 days
(no population controls experienced VTE during the index
admission of the matched CAB patient).
In supplementary analyses we first excluded the eight CAB
patients (0.19%) who had a primary VTE diagnosis in the index
admission, and their matched control groups. To examine the 90-
day risk of VTE occurring clearly after admission/hospitalisation,
we subsequently excluded CAB patients and hospitalised controls
with any VTE code in the index admission. Finally, we computed
the VTE risk after restriction to study subjects without recent
surgery/trauma (previous 90 days) or hospital admission (previous
180 days), cancer history or new cancer in the following 365 days,
or pregnancy in the 365 days surrounding the index date (here,
termed ‘‘classic’’ risk factors for VTE).
Venous Thromboembolism after Bacteraemia
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The proportional hazards assumption was checked graphically
by visual inspection of log- log plots. We used Stata 11.2 (Stata
Corp., College Station, TX) for all analyses.
Results
Study Subject Characteristics
We identified 4,389 individuals with a first diagnosis of CAB,
21,626 matched acutely hospitalised controls, and 43,831 matched
population controls. Among them, 176 CAB patients (4.0%), 709
hospitalised controls (3.3%), and 1,009 population controls (2.3%)
had a previous diagnosis of VTE and were excluded. Table 1
shows baseline characteristics of the remaining 4,213 CAB patients
and the matched hospitalised and population controls. The
majority of study participants were women (53.5%) and the
median age was 73 years (IQR 61–82). CAB patients and
hospitalised controls had a similar burden of pre-existing disease
(Supplementary Table S2). During the index hospitalisation,
10.9% of CAB patients had an intensive care unit stay as did
7.3% of hospitalised controls. Of note, mortality after CAB was
20.5% within 90 days and 29.3% within one year, whereas
mortality was lower in both control groups (Table 1).
VTE Risk
For CAB patients, the 90-day absolute risk of VTE was 1.1%
(Table 2), and the 91–365 day risk 0.5% (Table 3). Compared to
hospitalised controls, CAB patients had a moderately increased
risk of VTE during 0–90 days of follow-up (adjusted OR, 1.9; 95%
CI 1.4–2.7; Table 2) and during 91–365 days (adjusted HR 1.4;
95% CI 0.8–2.5; Table 3). Compared to population controls,
hospitalisation with CAB was associated with a greatly increased
risk for VTE within 90 days (adjusted OR, 23.4; 95% CI 12.9–
42.6; Table 2). Throughout the follow-up period most VTE events
were diagnosed during a hospital stay (96.7% of events for CAB
patients, 92.6% for hospitalised controls, and 86.7% for popula-
tion controls).
Twenty-six CAB patients (0.6%) experienced VTE during the
index admission. No population controls had a VTE diagnosis
during the hospitalisation of the corresponding matched cases, but










All CAB patients (4,213) 73.6 (61.2–82.2) 46.5 16.0 20.5 29.3
All hospital controls (20,084) 73.5 (60.9–82.1) 46.4 14.8 12.5 21.6
All population controls (41,121) 73.4 (60.9–82.0) 46.4 9.7 1.2 5.6
CAB patients according to:
Age, yrs
15–64 (1,306) 53.9 (42.2–59.9) 47.5 9.7 11.7 16.6
65–79 (1,568) 73.5 (69.8–77.1) 46.5 19.9 20.8 30.1
$80 (1,339) 85.2 (82.5–88.5) 45.3 17.6 28.8 40.7
Sex
Female (2,255) 73.8 (61.6–82.5) - 15.8 19.6 27.1
Male (1,958) 73.3 (60.4–81.9) - 16.2 21.6 31.8
Study period
1992–2002 (2,134) 73.4 (60.7–81.7) 46.3 15.1 21.7 29.9
2003–2010 (2,079) 73.8 (61.4–82.7) 46.7 16.9 19.4 28.6
Causative pathogen
Gram-positive (1,817) 70.8 (58.3–80.2) 51.9 15.2 22.0 30.1
S. aureus (302) 73.2 (61.7–81.3) 58.9 13.6 37.4 47.1
S. pneumoniae (994) 68.5 (55.8–78.9) 46.7 12.9 18.9 24.9
Other Gram-positive (521) 73.1 (61.5–81.6) 57.2 19.6 19.0 30.3
Gram-negative (2,120) 75.5 (63.7–83.0) 40.8 16.5 17.8 26.8
E. coli (1,468) 76.6 (66.3–83.6) 39.1 15.7 15.7 24.7
Other Gram-negative (652) 73.3 (56.8–81.7) 53.9 18.3 22.7 31.4
Polymicrobial/fungal (276) 78.4 (67.6–84.6) 54.4 17.8 31.5 43.1
Focus of infection
Respiratory tract (939) 69.1 (55.9–79.2) 48.6 14.6 18.0 23.8
Urinary tract (1,382) 77.1 (66.4–83.7) 37.8 15.1 12.3 23.0
Skin, bone, or joint (253) 71.3 (60.6–79.2) 56.1 14.2 17.0 27.7
Miscellaneous (655) 69.7 (53.8–79.3) 51.1 14.4 20.9 27.5
Unknown or multiple (986) 76.4 (65.6–84.2) 51.1 20.4 35.8 45.8
Abbreviations: IQR, inter-quartile range.
doi:10.1371/journal.pone.0086094.t001
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18 (,0.1%) had a VTE during 0–90 days of follow-up, which
corresponded to an adjusted OR of 13.9 (95% CI 7.2–26.8).
The VTE relative risk was especially elevated among young
study subjects, both within 90 days and during 91 to 365 days after
admission (vs. hospitalised controls, adjusted OR 2.7; 95% CI 1.4–
5.0, and adjusted HR, 3.4; 95% CI 1.2–9.9) (Table 2 and Table 3).
Gram-positive CAB was associated with a higher relative risk
for VTE vs. hospitalised controls within 0–90 days (adjusted OR,
2.5; 95% CI 1.6–4.1) than Gram-negative CAB (adjusted OR, 1.2;
95% CI 0.7–2.1) (Table 2). During 91–365 days of follow-up,
Gram-positive CAB remained a high-risk infection (adjusted HR
vs. hospitalised controls, 2.0; 95% CI 0.8–4.7; Table 3). Of note,
patients with Gram-positive bacteraemia were ,5 years younger
than patients with Gram-negative bacteraemia (Table 1) but had a
higher absolute 90-day risk of VTE (Table 2). In patients with
Gram-positive CAB, a particularly high 90-day risk of VTE was
found among patients with S. aureus infection (11/302, 3.6%),
while the risk was lower in patients with S. pneumonia infection (7/
994, 0.7%). Skin or bone/joint infection was also a high-risk
infection for VTE (0–90 day risk for VTE of 5.1%, 13/253), and
in this group the two most common infectious agents where S.
aureus (0–90 day risk for VTE of 7.2%, 6/83) and b-hemolytic
streptococci (0–90 day risk for VTE of 0.8%, 1/121).
After excluding CAB patients with a primary diagnosis of VTE
at the index admission, CAB remained associated with an
increased 90-day risk for VTE (OR vs. hospitalised controls, 1.6;
95% CI 1.1–2.3), see Supplementary Table S3. When examining
the 90-day risk for VTE after index admission, CAB was
associated with a 1.5-fold increased risk (OR) of VTE within 90
days when compared to hospitalised controls and a 9.2-fold
increased risk (OR) when compared to population controls
(Supplementary Table S3). In patients with no ‘‘classic’’ risk
factors for VTE, CAB was associated with a 90-day OR of 2.8
when compared to hospitalised controls (95% CI 1.6–4.8;
Supplementary Table S3).
Table 2. 0–90 day risk of a first VTE among patients with first hospital admission for CAB and matched hospitalised controls and
population controls, Northern Denmark, 1992–2010.





controls CAB vs. population controls
All study subjects 45/4,213 (1.1) 112/20,084 (0.6) 18/41,121 (0.0) 1.9 (1.4–2.7) 23.4 (12.9–42.6)
Age group, years
15–64 15/1,306 (1.2) 27/6,307 (0.4) 2/12,936 (0.0) 2.7 (1.4–5.0) 102.0 (14.7–710.4)
65–79 25/1,568 (1.6) 47/7,460 (0.6) 8/15,305 (0.1) 2.6 (1.6–4.2) 29.7 (13.1–67.3)
$80 5/1,339 (0.4) 38/6,317 (0.6) 8/12,880 (0.1) 0.7 (0.3–1.7) 6.3 (2.0–19.7)
Sex
Male 26/1,958 (1.3) 45/9,322 (0.5) 11/19,073 (0.1) 2.8 (1.7–4.6) 21.5 (10.5–43.7)
Female 19/2,255 (0.8) 67/10,762 (0.6) 7/22,041 (0.0) 1.4 (0.8–2.3) 27.6 (11.3–67.4)
Study period
1992–2002 23/2,134 (1.1) 43/10,260 (0.4) 7/20,905 (0.0) 2.6 (1.6–4.4) 29.3 (12.5–68.9)
2003–2010 22/2,079 (1.1) 69/9,824 (0.7) 11/20,216 (0.1) 1.5 (0.9–2.4) 19.7 (9.5–41.0)
Causative pathogen
Gram positive 26/1,817 (1.3) 49/8,651 (0.6) 3/17,781 (0.0) 2.5 (1.6–4.1) 77.0 (23.2–255.8)
S. aureus 11/302 (3.6) 8/1,426 (0.6) 2/2,947 (0.1) 7.2 (2.7–19.2) 51.3 (11.3–232.3)
S. pneumoniae 7/994 (0.7) 30/4,751 (0.6) 0/9,738 (0) 1.1 (0.5–2.5) -
Other Gram-positive 8/521 (1.5) 11/2,474 (0.4) 1/5,096 (0) 3.4 (1.4–8.4) 80.02 (10.0–639.2)
Gram negative 14/2,120 (0.7) 58/10,115 (0.6) 14/20,653 (0.1) 1.2 (0.7–2.1) 9.8 (4.6–20.6)
E. coli 8/1,468 (0.5) 36/6,992 (0.5) 11/14,389 (0.1) 1.1 (0.5–2.3) 6.9 (2.8–17.4)
Other Gram-negative 6/652 (0.9) 22/3,123 (0.7) 3/6,364 (0) 1.4 (0.5–3.5) 20.02 (5.0–80.0)
Polymicrobial and yeasts 5/276 (1.8) 5/1,318 (0.4) 1/2,687 (0) 5.0 (1.4–17.9) 49.22 (5.7–421.1)
Focus of infection
Urinary tract 7/1,382 (0.7) 33/6,582 (0.5) 12/13,431 (0.1) 1.3 (0.6–2.8) 7.4 (3.1–17.7)
Respiratory tract 5/939 (0.5) 28/4,491 (0.6) 0/9,180 (0) 0.8 (0.3–2.2) -
Skin, bone or joint 13/253 (5.1) 8/1,197 (0.7) 1/2,491 (0.0) 8.8 (3.4–22.6) 124.3 (16.2–953.0)
Miscellaneous 7/695 (1.0) 16/3,341 (0.5) 1/6,929 (0.0) 2.1 (0.9–5.3) 69.12 (8.5–561.4)
Unknown or multiple 11/944 (1.2) 27/4,473 (0.6) 3/9,313 (0.0) 1.8 (0.9–3.7) 17.7 (5.6–56.1)
Abbreviations: CI, confidence interval.
1Computed by conditional logistic regression. Controls matched for age, sex and calendar time act as reference group. All odds ratio estimates are controlled for
matching factors. Estimates for ‘‘All study subjects’’ are adjusted for cancer, cardiovascular disease, other comorbidity, and recent hospital contact. Subgroup analyses
are adjusted for any comorbidity.
2Not adjusted for comorbidity due to few events. A (2) denotes that the odds ratio could not be calculated because no events occurred among population controls.
doi:10.1371/journal.pone.0086094.t002
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Discussion
In this population-based cohort study, we found that CAB was
associated with a 1.1% risk of VTE within 90 days, nearly a
doubling of the risk compared to other acutely hospitalised
medical patients. Patients with gram positive bacteraemia,
especially S. aureus bacteraemia, had a particularly high risk for
VTE. When compared to matched hospitalised controls, S. aureus
infection increased the 90-day risk for VTE by 600%.
This is the first study to examine the risk of VTE after
microbiologically verified infection. It is also the largest cohort
study to date to examine infection-related VTE risks. A few
previous studies have detailed the absolute risk for VTE after
infectious disease. In a cohort study of 1,080 hospitalised patients
with presumed sepsis, 0.6% had VTE on admission, 1.3%
developed in-hospital VTE and 0.6% suffered VTE between
discharge and 1 year post-admission [2]. Similarly, pooled data on
adverse events from three clinical trials showed a 0.5–0.9% 28-day
risk for VTE in patients with severe sepsis [3]. Some clinical trials
that specifically addressed the impact of heparin prophylaxis
reported short-term absolute risk estimates for VTE ranging from
5 to 15% in medical patients hospitalised for acute infectious
disease [5,14]. The reason for this discrepancy is mainly that
asymptomatic deep venous thromboses accounted for the majority
of events in the trials.
Data on the relative risk increase for VTE conferred by
infectious disease are sparse. In a Spanish registry-based study
involving more than 1.5 million medical department discharges,
acute infectious disease was associated with 1.27-fold increased risk
for in-hospital VTE when compared to other diseases [4]. Using
data from the MEDENOX trial, Alikhan et al. found that
infectious disease was the only acute illness associated with a
significantly increased risk for VTE in hospitalised medical
patients (OR=1.74 within 14 days, compared with other medical
illness) [5]. To our knowledge only one previous study has
examined how the risk for VTE after hospitalisation for infections
varies according to the focus of the infection. In a case-control
study, Schmidt et al. found an up to 12-fold increased risk for
VTE within 2 weeks after hospitalisation for infections (vs.
Table 3. 91–365 day risk of first VTE diagnosis among patients with first hospital admission for CAB and matched hospitalised
controls and population controls, Northern Denmark, 1992–2010.
Risk, n/N (%) HR (95% CI)1 HR (95% CI)1







All study subjects 15/3,316 (0.5) 45/13,920 (0.3) 72/32,022 (0.2) 1.4 (0.8–2.5) 1.9 (1.0–3.3)
Age group, years
15–64 7/1,140 (0.6) 10/5,294 (0.2) 6/11,274 (0.1) 3.4 (1.2–9.9) 10.5 (3.4–32.6)
65–79 4/1,226 (0.3) 21/5,105 (0.4) 36/11,872 (0.3) 0.8 (0.3–2.4) 1.0 (0.4–2.9)
$80 4/950 (0.4) 14/3,521 (0.4) 30/8,876 (0.3) 1.1 (0.4–3.6) 1.2 (0.4–3.3)
Sex
Male 7/1,1519 (0.5) 21/6,313 (0.3) 30/14,628 (0.2) 1.5 (0.6–3.6) 2.0 (0.9–4.7)
Female 8/1,797 (0.4) 24/7,607 (0.3) 42/17,394 (0.2) 1.3 (0.6–3.0) 1.7 (0.8–3.8)
Study period
1992–2002 4/1,658 (0.2) 15/6,929 (0.2) 27/16,066 (0.2) 1.1 (0.4–3.5) 1.2 (0.4–3.6)
2003–2010 11/1,658 (0.7) 30/6,991 (0.4) 45/15,956 (0.3) 1.5 (0.7–3.1) 2.3 (1.2–4.4)
Causative pathogen
Gram positive 8/1,397 (0.6) 19/5,982 (0.3) 23/13,556 (0.2) 2.0 (0.8–4.7) 3.3 (1.5–7.5)
S. aureus 1/180 (0.6) 5/762 (0.7) 4/1,741 (0.2) 0.92 (0.1–7.5) 2.42 (0.3–21.9)
S. pneumoniae 4/802 (0.5) 7/3,489 (0.2) 9/7,798 (0.1) 2.8 (0.7–10.2) 4.2 (1.3–13.8)
Other Gram-positive 3/415 (0.7) 7/1,731 (0.4) 10/4,017 (0.2) 2.6 (0.6–11.7) 3.3 (0.8–12.8)
Gram negative 7/1,726 (0.4) 25/7,198 (0.3) 49/16,634 (0.3) 1.0 (0.4–2.5) 1.1 (0.5–2.5)
E. coli 5/1,233 (0.4) 16/5,066 (0.3) 34/11,828 (0.3) 1.3 (0.4–3.5) 1.2 (0.5–3.1)
Other Gram-negative 2/500 (0.4) 9/2,132 (0.4) 15/4,855 (0.3) 0.7 (0.1–3.4) 1.0 (0.2–4.4)
Polymicrobial and yeasts 0/186 (0) 1/740 (0.1) 0/1,783 (0) - -
Focus of infection
Urinary tract 4/1,206 (0.3) 14/4,942 (0.3) 31/11,556 (0.3) 1.2 (0.4–3.8) 1.1 (0.4–3.1)
Respiratory tract 3/767 (0.4) 5/3,335 (0.1) 10/7,451 (0.1) 2.4 (0.5–10.6) 2.8 (0.8–10.4)
Skin, bone or joint 0/198 (0) 5/819 (0.6) 4/1,921 (0.2) - -
Miscellaneous 1/545 (0.2) 9/2,356 (0.4) 8/5,309 (0.2) 0.3 (0.0–2.6) 1.2 (0.1–10.3)
Unknown or multiple 7/600 (1.2) 12/2,468 (0.5) 19/5,785 (0.3) 2.6 (0.9–7.0) 3.1 (1.3–7.4)
Abbreviations: HR, Hazard Ratio. CI, confidence interval.
1Computed by Cox regression stratified on matched groups. All hazard ratio estimates are controlled for matching factors (age, sex, calendar time). Estimates for ‘‘All
study subjects’’ are adjusted for cancer, cardiovascular disease, other comorbidity, and recent hospital contact. Subgroup analyses are adjusted for any comorbidity.
2Not adjusted for comorbidity due to few events. A (2) denotes that the hazard ratio could not be calculated.
doi:10.1371/journal.pone.0086094.t003
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population controls), with the highest increase after skin infections
[6]. Similarly, we found that microbiologically verified skin, bone
and joint infections were high-risk infections for VTE, particularly
if caused by S. aureus. That S. aureus skin and osteoarticular
infection may be associated with a high risk for VTE has
previously been suggested in case reports and smaller case series
[15–17].
In a recent clinical guideline on the use of VTE prophylaxis in
hospitalised medical patients, the American College of Physicians
stated that a decision to initiate prophylactic heparin therapy
should be based on an individualized assessment of the risk for
VTE and bleeding, and that current evidence does not support the
use of any specific VTE risk assessment tool [18]. Others have
advocated the use of large observational datasets to identify
inpatients who may benefit from VTE prophylaxis [19]. Our data
indicate that it might be advantageous to include CAB and/or S.
aureus infection in any future VTE risk assessment tool for use in
medical inpatients.
Infections may induce thromboembolism by a number of
mechanisms [20]. During systemic inflammatory activity, endo-
thelial cell apoptosis, tissue-factor expression, thrombin generation
and fibrin deposition is increased, while anticoagulatory pathways
and fibrinolysis are impaired [20,21]. Gram-positive bacteria,
including S. aureus, may have an exceptionally high propensity for
inducing thrombosis [17,22]. Immobilization is a risk factor for
VTE [12] and is pronounced during severe infection, especially
infection causing bone and joint pain [23].
Strengths of the present study include the large sample size and
microbiological verification of infection. We used computerized
medical databases of high quality and validated VTE codes [8,11].
Furthermore, we had complete and long follow-up.
However, this study also has limitations. The predictive value of
a VTE discharge code (from wards including outpatient clinics) in
the Danish registries approaches only 75% [11], which would bias
our estimates towards the null if misclassification was similar in
CAB patients and controls. The 90-day mortality among CAB
patients was 20.5% in our study, and it could be argued that some
patients may have died from an unidentified pulmonary embolism,
which may have led to an underestimation of the true pulmonary
embolism risk after CAB. Surveillance bias is possible, particularly
for infections that clinically mimic VTE. However, pneumonia
and skin infections caused by b-hemolytic streptococci were
associated with a relatively low absolute risk of VTE, indicating
that this bias is likely to be small if present at all. There is a risk
that VTE may have preceded CAB in some patients. To decrease
the risk for reverse causation, we restricted the study to patients
who had positive blood cultures on the day of admission. A further
argument against reverse causation is that our review of a sample
of medical records did not reveal instances in which the VTE
preceded the CAB. Another issue that should be taken into
consideration is the lack of data on in-hospital medication use. For
instance, anticoagulant use could have lowered the risk of VTE
and we may therefore have underestimated the VTE risk increase
associated with bacteremia in the absence of this treatment,
particularly versus population controls. We used information from
health-care databases to adjust for important risk factors for VTE,
but residual and unmeasured confounding remain possible, for
example thrombophilia.
We conclude that CAB is associated with a substantially
increased short-term risk for VTE. However, with the possible
exception of S. aureus infection, the absolute risk for VTE after
CAB is low.
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